Medicare Enrolled
Dr. Rattandeep Singh, MD
Rheumatology · Atlanta, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Singh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Singh?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Singh
Dr. Rattandeep Singh is a rheumatology specialist in Atlanta, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Singh performed 66,408 Medicare services across 1,230 unique beneficiaries.
Between the years covered by Open Payments, Dr. Singh received a total of $16,872 from 42 pharmaceutical and/or device companies across 928 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Singh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 14% volume in GA
$16,872 industry payments
Medicare Practice Summary
Medicare Utilization ↗66,408
Medicare services
Top 14% in GA for rheumatology
1,230
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,495 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
38,000 | $4 | $16 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
9,180 | $26 | $119 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
7,550 | $10 | $42 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
7,125 | $34 | $131 |
| Denosumab injection (Prolia/Xgeva) | 1,440 | $18 | $70 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
744 | $90 | $300 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
541 | $102 | $472 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
299 | $22 | $101 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
256 | $12 | $55 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
217 | $58 | $262 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
195 | $1 | $4 |
| Injection, methylprednisolone acetate, 40 mg | 144 | $6 | $25 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
94 | $1 | $17 |
| X-ray of hand, 2 views An X-ray imaging test of the hand using two different angles to visualize the bones and joints. |
87 | $25 | $120 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
86 | $128 | $400 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
79 | $54 | $339 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
78 | $120 | $400 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
75 | $62 | $250 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
48 | $4 | $18 |
| Knee X-ray, 3 views An X-ray imaging test of the knee joint that captures three different angles to evaluate the bones and surrounding structures. |
38 | $32 | $154 |
| Shoulder X-ray, 2+ views An X-ray imaging test of the shoulder joint using at least two different angles to visualize the bones and surrounding structures. |
28 | $27 | $120 |
| Wrist X-ray, 2 views An X-ray imaging test of the wrist using two different angles to visualize the bones and joints. |
26 | $27 | $120 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
21 | $39 | $137 |
| X-ray of lower and sacral spine, 2-3 views An X-ray imaging test that captures 2 to 3 views of the lower back and sacral spine to visualize the bones and joints in this area. |
15 | $30 | $150 |
| X-ray of upper spine, 2-3 views An X-ray imaging test of the upper spine using two to three different angles to visualize the bones and structures. |
14 | $27 | $100 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
14 | $82 | $250 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
14 | $41 | $150 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
36.7% high complexity
61.4% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,872
Total received (2018-2024)
Avg $2,410/year across 7 years
Top 21% in GA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
928
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,872 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,300
2023
$3,636
2022
$2,915
2021
$1,633
2020
$1,295
2019
$1,475
2018
$1,617
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$829
ABBVIE INC.
$789
Janssen Biotech, Inc.
$512
GlaxoSmithKline, LLC.
$190
Organon Llc
$187
Novartis Pharmaceuticals Corporation
$175
UCB, Inc.
$173
AstraZeneca Pharmaceuticals LP
$170
PFIZER INC.
$152
Octapharma USA, Inc.
$128
Lilly USA, LLC
$114
ANI Pharmaceuticals, Inc.
$102
Mallinckrodt Hospital Products Inc.
$101
E.R. Squibb & Sons, L.L.C.
$94
Alexion Pharmaceuticals, Inc.
$91
Teva Pharmaceuticals USA, Inc.
$91
GENZYME CORPORATION
$79
Aurinia Pharma U.S., Inc.
$75
Kiniksa Pharmaceuticals International, plc
$75
Sandoz Inc.
$64
Fresenius Kabi USA, LLC
$55
Almatica Pharma LLC
$19
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
SCILEX PHARMACEUTICALS INC.
$17
Top 3 companies account for 49.5% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$3,158
AbbVie Inc.
$1,578
Janssen Biotech, Inc.
$1,431
ABBVIE INC.
$1,272
Novartis Pharmaceuticals Corporation
$1,240
Horizon Therapeutics plc
$961
PFIZER INC.
$869
UCB, Inc.
$863
Lilly USA, LLC
$631
AbbVie, Inc.
$475
GlaxoSmithKline, LLC.
$472
Aurinia Pharma U.S., Inc.
$414
AstraZeneca Pharmaceuticals LP
$407
Celgene Corporation
$368
Alexion Pharmaceuticals, Inc.
$215
Organon Llc
$187
Genentech USA, Inc.
$187
Horizon Pharma plc
$176
Antares Pharma, Inc.
$172
E.R. Squibb & Sons, L.L.C.
$162
GENZYME CORPORATION
$156
SANOFI-AVENTIS U.S. LLC
$153
Mallinckrodt Hospital Products Inc.
$135
Octapharma USA, Inc.
$128
Organon LLC
$115
Sandoz Inc.
$102
ANI Pharmaceuticals, Inc.
$102
Galt Pharmaceuticals, LLC
$100
Teva Pharmaceuticals USA, Inc.
$91
MEDEXUS PHARMA, INC.
$86
Boehringer Ingelheim Pharmaceuticals, Inc.
$79
Kiniksa Pharmaceuticals International, plc
$75
Fresenius Kabi USA, LLC
$72
Janssen Scientific Affairs, LLC
$52
Sobi, Inc
$43
MEDAC PHARMA, INC.
$31
Kiniksa Pharmaceuticals, Ltd.
$29
Almatica Pharma LLC
$19
FIDIA PHARMA USA INC.
$18
Kowa Pharmaceuticals America, Inc.
$18
SCILEX PHARMACEUTICALS INC.
$17
Ironwood Pharmaceuticals, Inc
$13
Top 3 companies account for 36.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · DUEXIS · EVENITY · Enbrel · FORTEO · GLOPERBA · HADLIMA · HUMIRA · HYALGAN · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · Kineret · LINZESS · LOREEV XR · LUPKYNIS · LYRICA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · OTREXUP · Orphengesic Forte · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI · SIMPONI ARIA · SKYRIZI · SOVUNA · STELARA · STRENSIQ · SYNVISC-ONE · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tyenne · Ultomiris · VIMOVO · XELJANZ · XYOSTED
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
90
Per 100K population
8.4
County median income
$91,490
Nearest hospital
PIEDMONT HOSPITAL, INC
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Singh is a mixed practice specialist, with above-average Medicare volume (top 14% in GA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Singh experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Singh performed 38,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Singh receive payments from pharmaceutical companies?
Yes. Dr. Singh received a total of $16,872 from 42 companies across 928 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Singh's costs compare to other rheumatologists in Atlanta?
Dr. Singh's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Singh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Atlanta
Browse rheumatologists in Atlanta ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in GA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in GA
Which GA rheumatologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology